NCT07155174 2026-03-17
SEZanne
AbbVie
Phase 2 Recruiting
Clinical Trials
18 trialsNCT05533775 2026-03-06
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06646276 2026-03-04
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT07005128 2026-02-27
DeLLphi-312
Amgen
Phase 3 Recruiting
NCT07227597 2026-02-20
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06712355 2026-02-13
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
BioNTech SE
Phase 3 Recruiting
NCT06230224 2026-02-06
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT07268040 2026-01-12
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06741644 2026-01-09
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT06132113 2025-12-17
DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Boehringer Ingelheim
Phase 1 Recruiting
NCT07245446 2025-11-24
A Study of Ivonescimab in First-Line ES-SCLC
Akeso
Phase 2 Recruiting
NCT05595460 2025-08-12
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
RayzeBio, Inc.
Phase 1 Recruiting
NCT07009457 2025-07-04
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT06030258 2025-04-30
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06897579 2025-04-11
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT06792253 2025-01-24
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc
Phase 3 Recruiting
NCT06372626 2024-06-14
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Recruiting